Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. - Wikidata - awgldk - TriplyDB

Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk.

Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk.

http://www.wikidata.org/entity/Q36055396

about

The phospholipid scramblases 1 and 4 are cellular receptors for the secretory leukocyte protease inhibitor and interact with CD4 at the plasma membrane WFDC1/ps20 is a novel innate immunomodulatory signature protein of human immunodeficiency virus (HIV)-permissive CD4+ CD45RO+ memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infection Viral and immunological factors associated with breast milk transmission of SIV in rhesus macaques Innate immune defences in the human endometrium Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid.Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor.Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity Longitudinal assessment of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon responses during the first year of life in HIV-1-infected infants.The mouth: a gateway or a trap for HIV?Phenotypic characterization of HIV-specific CD8+ T cells during early and chronic infant HIV-1 infection.Toll-like receptor variants are associated with infant HIV-1 acquisition and peak plasma HIV-1 RNA level.Oral transmission of HIV, reality or fiction? An update.Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections.The role of cell-associated virus in mother-to-child HIV transmission.Genetic and Immunological Factors Involved in Natural Resistance to HIV-1 Infection.Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids Systemic and mucosal differences in HIV burden, immune, and therapeutic responses Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action.Alpha-defensins in the prevention of HIV transmission among breastfed infants.The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.Breast-feeding and Transmission of HIV-1.Anti-HIV-1 activity of elafin is more potent than its precursor's, trappin-2, in genital epithelial cells The Presence and Anti-HIV-1 Function of Tenascin C in Breast Milk and Genital Fluids.Human leukocyte antigen (HLA) B*18 and protection against mother-to-child HIV type 1 transmission.High uptake of postpartum hormonal contraception among HIV-1-seropositive women in Kenya Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection.Short communication: Increased expression of secretory leukocyte protease inhibitor in oral mucosa of Colombian HIV type 1-exposed seronegative individuals.Exclusive breastfeeding reduces risk of mortality in infants up to 6 mo of age born to HIV-positive Tanzanian women Impact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract.Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women.The oral mucosa immune environment and oral transmission of HIV/SIV.The detection of cytomegalovirus DNA in maternal plasma is associated with mortality in HIV-1-infected women and their infants.Estimation and comparison of salivary secretory leukocyte protease inhibitor in human immunodeficiency virus patients and healthy individuals.Cervical intraepithelial neoplasia is associated with genital tract mucosal inflammation.Older rhesus macaque infants are more susceptible to oral infection with simian-human immunodeficiency virus 89.6P than neonates.SLPI and elafin: multifunctional antiproteases of the WFDC family.Antiviral activities of whey proteins.In-utero infection with HIV-1 associated with suppressed lymphoproliferative responses at birth.Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya.

P2860

Q21143809-7504FDEA-F4C4-4E2A-B5D3-4ABA00398EBC Q24657262-A73CD1EB-8389-430A-B185-009833A29A5B Q24795604-6D2E5BEA-8B05-431D-8AB6-EA38A0C36C50 Q24801159-6C306D62-CF59-4B98-A382-E7A25C179878 Q33399887-3A1F40ED-9A25-4B70-8A53-655D5D4BFF8F Q33715960-D3CA0264-1035-4D57-AD41-B18511B78A2A Q33780434-5A5D22CB-906C-4973-A0CA-5E9E361156B1 Q33843438-22E7DAC8-CC9F-4F7B-8307-057DF50FF5A0 Q33874252-1550B42C-C019-4DE2-A25E-D4F9C23D45CE Q33927135-4A63DA54-0669-4D29-BCE6-CB6E39AD1856 Q34014618-E2636F4C-5AB3-4519-A665-75C136747F72 Q34526020-105C7F6E-1FA5-423A-958B-B087AE6814BC Q34680240-BFE2BDCA-DAC9-48F2-B3FB-8F2C833D98AE Q35000080-A1C45073-79BF-4F3E-B5F8-18E63B51AF5D Q35030053-EE5620B9-2805-480F-BB03-47D30A5E9239 Q35075174-C093783F-0E99-494B-A636-F214483A1F65 Q35190200-1A0BBBA1-7296-475B-9B81-06B2FDC6076D Q35458113-7688ACD3-5553-47EB-B456-47C2EB276400 Q35577249-02777282-B969-4BB0-BA09-647006ACE8D8 Q35591075-261FE63C-6702-440F-B7D6-0D93B4A30BE1 Q35628427-07B424AA-F01B-42CC-A407-CB72E86BFF46 Q35868058-AF7E34F2-8770-4DF0-9BC2-BAC8F2522C2E Q36018536-A30A8E30-8D4C-4C08-AB6C-6138C93A6C2E Q36049157-C82CF356-680E-4167-A58D-0DE996B4132C Q36069338-357DBD87-CD2F-468F-9032-6BE94FFD3548 Q36095139-92B65D12-4AFE-4A3C-93D6-E002570EF291 Q36177527-FC68EC43-8762-4991-A855-2954B2F2E578 Q36317084-43C03BA4-65F8-4E81-B57A-AE8399DC2DD2 Q36640429-B193DAD8-33AD-4056-8A7A-9B765B3F393A Q36898823-B7A98174-A607-4111-BBA6-8EEE2D233DD3 Q36996000-AA16A3F5-575B-411E-8835-857E1F9B9DA9 Q37290154-719123DB-B064-4768-9574-6D4702777B57 Q37336986-C7D250DF-80BD-41A3-A45C-12D927850BB2 Q37596710-E1DA3215-6C82-44C3-BE09-91382D6FB727 Q37693958-649F4C8B-8E7E-4F42-9816-2A026496C8E4 Q37742900-32999CF3-9C89-4E4B-9940-8EC798371DEB Q37936541-64671F58-1718-4535-9F7A-6ABF3C5D1D93 Q38551779-DA1D1720-D25E-4DF5-9389-028CC297588B Q42214247-B75FFC08-7D22-4227-BD00-DE8718C4C264 Q45394795-0045C74D-B92C-45F4-A050-515CA918A355

P2860

Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk.

http://www.wikidata.org/entity/Q36055396

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Salivary secretory leukocyte p ...... us type 1 through breast milk.

@ast

Salivary secretory leukocyte p ...... us type 1 through breast milk.

@en

type

label

Salivary secretory leukocyte p ...... us type 1 through breast milk.

@ast

Salivary secretory leukocyte p ...... us type 1 through breast milk.

@en

prefLabel

Salivary secretory leukocyte p ...... us type 1 through breast milk.

@ast

Salivary secretory leukocyte p ...... us type 1 through breast milk.

@en

P1433

Q36055396-AC8262B8-10BE-4AF9-9867-E4E7D5A6EABF

P1476

Q36055396-66DDD4EC-D656-422C-A3FC-C0FF5D1945A3

P2093

Q36055396-2B388A2C-4BB3-489C-9C2B-36F5F9132AE9

Q36055396-3881EF81-0386-4DCF-B75D-4DD48BB9BA18

Q36055396-49921228-C24A-42AE-8F19-6317DF268719

Q36055396-A74FD473-378D-4585-8FD5-DBBBA6163134

Q36055396-A8E645E8-789C-4D86-B3E0-3AE70878484D

Q36055396-AA107230-E1AA-46D3-B5EE-5C3C19EEE856

Q36055396-AB6BAF26-5805-4F07-9BAC-1C01E3DEB7D4

Q36055396-EB3EB649-F239-4345-A5C0-C57E6DADCBD1

P2860

Q36055396-068346EF-7DAC-440F-863C-C0BE05E39962

Q36055396-46C835A5-9CDF-4E45-95EF-ABAF23D322A3

Q36055396-865E25C9-F4D7-4D86-8E52-1C7685C74190

Q36055396-A3F7C007-6F5B-4407-9E6F-3D84B5D0A9E8

Q36055396-B5D21107-3C2C-4CEA-8266-E9A56202A1F6

Q36055396-C9FF3D02-1659-4052-85FC-2D6EF2EB0E53

Q36055396-CAF982A3-0EDA-4CED-AFAB-0F736F5E6634

Q36055396-CDAF806A-F04F-4EEA-8124-1EC2FB73FEE0

Q36055396-D1BEB790-1C67-4FDA-997A-90A52B3F2F0C

Q36055396-F0DE9698-C0E6-45A9-AFEC-B58F7F60AD7E

P304

Q36055396-85940227-5E5B-48A3-8A59-37E37E648B41

P31

Q36055396-108A2556-A466-4EBE-9E76-46DA77540AA8

P356

Q36055396-4C1A84AB-26E8-49D6-83F6-FBDBB1841D88

P407

Q36055396-16D742F8-5476-4039-A40C-B10B9C07A960

P433

Q36055396-D8B6A9EA-9E28-43DF-A1AB-08F4365D26DE

P478

Q36055396-6E6866B0-13EC-4A61-A90F-C40577B0FA9C

P577

Q36055396-F142AEC4-741E-4AF3-BD0B-45E5E3BAF647

P5875

Q36055396-743F5480-EC9E-4D7A-B2B9-730846BD520A

P698

Q36055396-148FB4E9-E8F6-4B3A-ADCA-3DB0AD11789B

P932

Q36055396-EE1A35B1-7720-4207-A446-0A4648039BD4

P356

P1433

The Journal of Infectious Diseases

P1476

Salivary secretory leukocyte p ...... us type 1 through breast milk.

@en

P2093

Barbra A Richardson

http://www.w3.org/2001/XMLSchema#string

Carey Farquhar

http://www.w3.org/2001/XMLSchema#string

Dorothy A Mbori-Ngacha

http://www.w3.org/2001/XMLSchema#string

Grace C John-Stewart

http://www.w3.org/2001/XMLSchema#string

Joan K Kreiss

http://www.w3.org/2001/XMLSchema#string

Lena Horani

http://www.w3.org/2001/XMLSchema#string

Rose K Bosire

http://www.w3.org/2001/XMLSchema#string

Thomas C VanCott

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a novel secretory leukocyte protease inhibitor-binding protein involved in membrane phospholipid movement

Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro

Endogenous mucosal antiviral factors of the oral cavity.

Rapid method for screening dried blood samples on filter paper for human immunodeficiency virus type 1 DNA

Human immunodeficiency virus (HIV)-specific cellular immune responses in newborns exposed to HIV in utero.

Mother-to-child transmission of human immunodeficiency virus type 1.

Cervical human immunodeficiency virus type 1 shedding is associated with genital beta-chemokine secretion.

Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission.

Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I.

Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription.

P304

1173-1176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/343805

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

186

http://www.w3.org/2001/XMLSchema#string

P577

2002-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11102772

http://www.w3.org/2001/XMLSchema#string

P698

12355371

http://www.w3.org/2001/XMLSchema#string

P932

3382060

http://www.w3.org/2001/XMLSchema#string